Cartesian Therapeutics (RNAC) Return on Sales: 2016-2025
Historic Return on Sales for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -76.75%.
- Cartesian Therapeutics' Return on Sales fell 7239.00% to -76.75% in Q3 2025 from the same period last year, while for Sep 2025 it was -76.75%, marking a year-over-year decrease of 7239.00%. This contributed to the annual value of -1.99% for FY2024, which is 646.00% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Return on Sales stood at -76.75%, which was up 0.60% from -77.21% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Return on Sales registered a high of 0.22% during Q3 2022, and its lowest value of -77.21% during Q2 2025.
- In the last 3 years, Cartesian Therapeutics' Return on Sales had a median value of -3.75% in 2024 and averaged -16.79%.
- Its Return on Sales has fluctuated over the past 5 years, first soared by 970bps in 2021, then plummeted by 7,346bps in 2025.
- Over the past 5 years, Cartesian Therapeutics' Return on Sales (Quarterly) stood at -0.16% in 2021, then soared by 36bps to 0.19% in 2022, then plummeted by 948bps to -9.29% in 2023, then surged by 835bps to -0.94% in 2024, then tumbled by 7,239bps to -76.75% in 2025.
- Its last three reported values are -76.75% in Q3 2025, -77.21% for Q2 2025, and -1.29% during Q1 2025.